Impact of clonal hematopoiesis on the time from diagnosis to thrombopoietin receptor agonist (TPO-RA) and to second-line treatment. (A) Time to thrombopoietin receptor agonists treatment according to NGS positivity for CHIP mutations. (B) Time to second-line treatment (any treatment option) in patients with ITP according to NGS positivity for CHIP mutations.